Luiz Belardinelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luiz Belardinelli has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Sridharan Rajamani
Department of Biological Sciences, Gilead Sciences Inc., 7601 Dumbarton Cir, Fremont, CA 94555, USA
4 shared publications - Arvinder K. Dhalla
Department of Biological Sciences, Gilead Sciences Inc., 7601 Dumbarton Cir, Fremont, CA 94555, USA
3 shared publications - Charles Antzelevitch
Lankenau Institute for Medical Research Wynnewood Pennsylvania USA
2 shared publications - Elfatih Elzein
Department of Bioorganic Chemistry, CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304, USA
2 shared publications J C Shryock
CV Therapeutics Inc, Palo Alto, CA 94304, USA
2 shared publicationsJohn C. Shryock
Pharmacology and Translational Biomedical Research, CV Therapeutics Inc., 3172 Porter Drive, Palo Alto, CA 94304, USA
2 shared publications
Latest Publications
- 1 June 2014
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 63 (6) , 512-519
Selective Inhibition of the Late Sodium Current has No Adverse Effect on Electrophysiological or Contractile Function of the Normal Heart
Inhibition of cardiac late Na(+) current (I(Na,L)) decreases sodium-dependent calcium overload in diseased hearts. Because INa,L is small in the absence of disease, its inhibition is not expected to significantly alter function of the normal heart. To test this hypothesis, we determined the effects of GS-458967 (GS967), a novel selective inhibitor of I(Na,L) (IC(50) = 0.13 μM), on cardiac function and hemodynamics. The bradycardic agent ivabradine and the Na(+) channel blocker flecainide were used for comparison. A single per os administration of GS967 (5 mg/kg) had no effect on blood pressure or heart rate (HR) in unanesthetized rats. In anesthetized rats, GS967 (0.6 ± 0.1 μM plasma concentration) had no significant effect on HR, PR or QRS electrocardiogram intervals, or contraction. Flecainide (8 mg/kg) slowed HR by 23% ± 3% (P < 0.001), prolonged the PR and QRS intervals by 42% ± 8% and 64% ± 12% (P < 0.001), and had a significant negative inotropic effect. Ivabradine (3 mg/kg) slowed HR by 36% ± 6% (P < 0.001). In rat and rabbit isolated perfused hearts, GS967 (0.1-3 μM) had no significant effects on HR, QRS interval, or contractile function. The results show that selective inhibition of cardiac I(Na,L) is not associated with chronotropic, dromotropic, inotropic, or hemodynamic changes.
- 1 June 2014
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 63 (6) , 512-519
Selective Inhibition of the Late Sodium Current has No Adverse Effect on Electrophysiological or Contractile Function of the Normal Heart
Inhibition of cardiac late Na(+) current (I(Na,L)) decreases sodium-dependent calcium overload in diseased hearts. Because INa,L is small in the absence of disease, its inhibition is not expected to significantly alter function of the normal heart. To test this hypothesis, we determined the effects of GS-458967 (GS967), a novel selective inhibitor of I(Na,L) (IC(50) = 0.13 μM), on cardiac function and hemodynamics. The bradycardic agent ivabradine and the Na(+) channel blocker flecainide were used for comparison. A single per os administration of GS967 (5 mg/kg) had no effect on blood pressure or heart rate (HR) in unanesthetized rats. In anesthetized rats, GS967 (0.6 ± 0.1 μM plasma concentration) had no significant effect on HR, PR or QRS electrocardiogram intervals, or contraction. Flecainide (8 mg/kg) slowed HR by 23% ± 3% (P < 0.001), prolonged the PR and QRS intervals by 42% ± 8% and 64% ± 12% (P < 0.001), and had a significant negative inotropic effect. Ivabradine (3 mg/kg) slowed HR by 36% ± 6% (P < 0.001). In rat and rabbit isolated perfused hearts, GS967 (0.1-3 μM) had no significant effects on HR, QRS interval, or contractile function. The results show that selective inhibition of cardiac I(Na,L) is not associated with chronotropic, dromotropic, inotropic, or hemodynamic changes.
- 2 February 2011
- Published by Elsevier in Biophysical Journal
- Vol. 100 (3) , 421a
Enhancement of Slow Inactivation of Voltage-Gated Na+ Channels by Ranolazine
- 2 February 2011
- Published by Elsevier in Biophysical Journal
- Vol. 100 (3) , 421a
Enhancement of Slow Inactivation of Voltage-Gated Na+ Channels by Ranolazine
- 31 January 2010
- Published by Elsevier in Biophysical Journal
- Vol. 98 (3) , 113a-113
Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics
- 31 January 2010
- Published by Elsevier in Biophysical Journal
- Vol. 98 (3) , 113a-113
Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics
- 28 May 2009
- Published by Springer Nature
- No. 193,p. 271-295
A1 Adenosine Receptor: Role in Diabetes and Obesity
Adenosine mediates its diverse effects via four subtypes (A1, A2A, A2B and A3) of G-protein-coupled receptors. The A1 adenosine receptor (A1AR) subtype is the most extensively studied and is well characterized in various organ systems. The A1ARs are highly expressed in adipose tissue, and endogenous adenosine has been shown to tonically activate adipose tissue A1ARs. Activation of the A1ARs in adipocytes reduces adenylate cyclase and cAMP content and causes inhibition of lipolysis. The role of A1ARs in lipolysis has been well characterized by using several selective A1AR agonists as well as A1AR knockout mice. However, the contribution of A1ARs to the regulation of lipolysis in pathological conditions like insulin resistance, diabetes and dyslipidemia, where free fatty acids (FFA) play an important role, has not been well characterized. Pharmacological agents that reduce the release of FFA from adipose tissue and thus the availability of circulating FFA have the potential to be useful for insulin resistance and hyperlipidemia. Toward this goal, several selective and efficacious agonists of the A1ARs are now available, and some have entered early-phase clinical trials; however, none have received regulatory approval yet. Here we review the existing knowledge on the role of A1ARs in insulin resistance, diabetes and obesity, and the progress made in the development of A1AR agonists as antilipolytic agents, including the challenges associated with this approach.
- 28 May 2009
- Published by Springer Nature
- No. 193,p. 271-295
A1 Adenosine Receptor: Role in Diabetes and Obesity
Adenosine mediates its diverse effects via four subtypes (A1, A2A, A2B and A3) of G-protein-coupled receptors. The A1 adenosine receptor (A1AR) subtype is the most extensively studied and is well characterized in various organ systems. The A1ARs are highly expressed in adipose tissue, and endogenous adenosine has been shown to tonically activate adipose tissue A1ARs. Activation of the A1ARs in adipocytes reduces adenylate cyclase and cAMP content and causes inhibition of lipolysis. The role of A1ARs in lipolysis has been well characterized by using several selective A1AR agonists as well as A1AR knockout mice. However, the contribution of A1ARs to the regulation of lipolysis in pathological conditions like insulin resistance, diabetes and dyslipidemia, where free fatty acids (FFA) play an important role, has not been well characterized. Pharmacological agents that reduce the release of FFA from adipose tissue and thus the availability of circulating FFA have the potential to be useful for insulin resistance and hyperlipidemia. Toward this goal, several selective and efficacious agonists of the A1ARs are now available, and some have entered early-phase clinical trials; however, none have received regulatory approval yet. Here we review the existing knowledge on the role of A1ARs in insulin resistance, diabetes and obesity, and the progress made in the development of A1AR agonists as antilipolytic agents, including the challenges associated with this approach.
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 250a
Mechanism of the Preferential Block of the Atrial Sodium Current by Ranolazine
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 250a
Mechanism of the Preferential Block of the Atrial Sodium Current by Ranolazine
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 623a-624a
Blocking the Late Sodium Current Reduces Intracellular Sodium Accumulation During Sodium Pump Inhibition
- 1 February 2009
- Published by Elsevier in Biophysical Journal
- Vol. 96 (3) , 623a-624a
Blocking the Late Sodium Current Reduces Intracellular Sodium Accumulation During Sodium Pump Inhibition
- Open Access
- 20 June 2008
- Published by Springer Nature in Purinergic Signalling
- Vol. 4 (4) , 407-408
The first second-generation adenosine drug enters the US market
- 20 June 2008
- Published by Springer Nature in Purinergic Signalling
- Vol. 4 (4) , 407-408
Open AccessThe first second-generation adenosine drug enters the US market
- 1 March 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (6) , 1128-1132
Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium
This commentary on the review by DA Saint in the current issue of the British Journal of Pharmacology focuses on the pathological role of late I(Na) in the heart, the evidence supporting inhibition of late I(Na) as a therapeutic target in ischaemic heart disease, and the therapeutic applications and challenges for development of new late I(Na) inhibitors. Recent reports from a large clinical outcome trial (MERLIN) of ranolazine, a drug known to inhibit late I(Na), indicated that it was safe and reduced recurrent ischaemia and arrhythmic activity. In combination with other results indicating that inhibition of late I(Na) reduces ischaemia, myocardial Ca(2+) overload, and electrical and mechanical dysfunction when late I(Na) is increased, the new clinical trial results suggest that reduction of cardiac late I(Na) is safe and therapeutically beneficial.
- 1 March 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (6) , 1128-1132
Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium
This commentary on the review by DA Saint in the current issue of the British Journal of Pharmacology focuses on the pathological role of late I(Na) in the heart, the evidence supporting inhibition of late I(Na) as a therapeutic target in ischaemic heart disease, and the therapeutic applications and challenges for development of new late I(Na) inhibitors. Recent reports from a large clinical outcome trial (MERLIN) of ranolazine, a drug known to inhibit late I(Na), indicated that it was safe and reduced recurrent ischaemia and arrhythmic activity. In combination with other results indicating that inhibition of late I(Na) reduces ischaemia, myocardial Ca(2+) overload, and electrical and mechanical dysfunction when late I(Na) is increased, the new clinical trial results suggest that reduction of cardiac late I(Na) is safe and therapeutically beneficial.
Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine
Pathological conditions linked to imbalances in oxygen supply and demand (for example, ischaemia, hypoxia and heart failure) are associated with disruptions in intracellular sodium ([Na+]i) and calcium ([Ca2+]i) concentration homeostasis of myocardial cells. A decreased efflux or increased influx of sodium may cause cellular sodium overload. Sodium overload is followed by an increased influx of calcium through sodium-calcium exchange. Failure to maintain the homeostasis of [Na+]i and [Ca2+]i leads to electrical instability (arrhythmias), mechanical dysfunction (reduced contractility and increased diastolic tension) and mitochondrial dysfunction. These events increase ATP hydrolysis and decrease ATP formation and, if left uncorrected, they cause cell injury and death. The relative contributions of various pathways (sodium channels, exchangers and transporters) to the rise in [Na+]i remain a matter of debate. Nevertheless, both the sodium-hydrogen exchanger and abnormal sodium channel conductance (that is, increased late sodium current (INa)) are likely to contribute to the rise in [Na+]i. The focus of this review is on the role of the late (sustained/persistent) INa in the ionic disturbances associated with ischaemia/hypoxia and heart failure, the consequences of these ionic disturbances, and the cardioprotective effects of the antianginal and anti-ischaemic drug ranolazine. Ranolazine selectively inhibits late INa, reduces [Na+]i-dependent calcium overload and attenuates the abnormalities of ventricular repolarisation and contractility that are associated with ischaemia/reperfusion and heart failure. Thus, inhibition of late INa can reduce [Na+]i-dependent calcium overload and its detrimental effects on myocardial function.
Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine
Pathological conditions linked to imbalances in oxygen supply and demand (for example, ischaemia, hypoxia and heart failure) are associated with disruptions in intracellular sodium ([Na+]i) and calcium ([Ca2+]i) concentration homeostasis of myocardial cells. A decreased efflux or increased influx of sodium may cause cellular sodium overload. Sodium overload is followed by an increased influx of calcium through sodium-calcium exchange. Failure to maintain the homeostasis of [Na+]i and [Ca2+]i leads to electrical instability (arrhythmias), mechanical dysfunction (reduced contractility and increased diastolic tension) and mitochondrial dysfunction. These events increase ATP hydrolysis and decrease ATP formation and, if left uncorrected, they cause cell injury and death. The relative contributions of various pathways (sodium channels, exchangers and transporters) to the rise in [Na+]i remain a matter of debate. Nevertheless, both the sodium-hydrogen exchanger and abnormal sodium channel conductance (that is, increased late sodium current (INa)) are likely to contribute to the rise in [Na+]i. The focus of this review is on the role of the late (sustained/persistent) INa in the ionic disturbances associated with ischaemia/hypoxia and heart failure, the consequences of these ionic disturbances, and the cardioprotective effects of the antianginal and anti-ischaemic drug ranolazine. Ranolazine selectively inhibits late INa, reduces [Na+]i-dependent calcium overload and attenuates the abnormalities of ventricular repolarisation and contractility that are associated with ischaemia/reperfusion and heart failure. Thus, inhibition of late INa can reduce [Na+]i-dependent calcium overload and its detrimental effects on myocardial function.